期刊文献+

非布司他在高尿酸血症伴慢性肾病患者中的药代动力学及药效学评价 被引量:1

下载PDF
导出
摘要 目的评价非布司他在高尿酸血症伴慢性肾病患者中的药代动力学及药效学。方法 45例高尿酸血症伴慢性肾病患者,随机分成1组、2组和3组,各15例。1组接受单次空腹口服40 mg非布司他,2组接受单次空腹口服80 mg非布司他, 3组接受单次空腹口服120 mg非布司他。2组患者在单次给药后,继续空腹口服80 mg非布司他进行治疗, 1次/d,连续服药1个月。比较三组患者治疗后的血药浓度和血尿酸水平。结果治疗前,三组患者血尿酸水平比较,差异无统计学意义(P>0.05),治疗后, 1组患者血尿酸水平为(8.39±1.24)mg/dl, 2组患者血尿酸水平为(6.63±1.44)mg/dl, 3组患者血尿酸水平为(8.32±1.37)mg/dl, 2组患者血尿酸水平明显低于1组、2组,差异具有统计学意义(P<0.05)。结论高尿酸血症伴发慢性肾病患者接受非布司他治疗后,其血尿酸水平明显下降,患者的预后效果比较理想,临床中可以进行推广使用。
作者 罗明华
出处 《中国实用医药》 2019年第1期112-113,共2页 China Practical Medicine
  • 相关文献

参考文献10

二级参考文献125

  • 1何培根.风湿性疾病的诊断标准[J].临床内科杂志,1995,12(3):13-14. 被引量:50
  • 2全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:710
  • 3Takano Y,Hase-Aoki K,Horiuchi H,et al.Selectivity of febuxostat,a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci,2005,76(16):1835-1847.
  • 4Bruce SP.Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Ann Pharmacother,2006,40(12):2187-2194.
  • 5Mayer MD,Khosravan R,Vernillet L,et al.Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.Am J Ther,2005,12(1):22-34.
  • 6Khosravan R,Grabowski BA,Wu JT,et al.Pharmacokinetics,pharmacodynamics and safety of febuxostat,a non-purine selective inhibitor of xanthine oxidase,in a dose escalation study in healthy subjects.Clin Pharmacokinet,2006,45(8):821-841.
  • 7Khosravan R,Grabowski BA,Mayer MD,et al.The effect of mild and moderate hepatic impairment on pharmacokinetics,pharmacodynamics,and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase.J Clin Pharmacol,2006,46(1):88-102.
  • 8Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day,multicenter,phaseⅡ,randomized,double-blind,placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout.Arthritis Rheum,2005,52(3):916-923.
  • 9Schumacher HR,Becker MA,Wortmann RL,et al.Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial.Arthritis Rheum,2008,59(11):1540-1548.
  • 10Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.N Engl J Med,2005,353(23):2450-2461.

共引文献155

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部